8-K: InMed Pharmaceuticals Secures $5 Million in Private Placement to Fund Pipeline Development and Operations

InMed Pharmaceuticals Inc. has successfully closed a $5 million private placement, issuing pre-funded warrants and preferred investment options to a single institutional investor, with proceeds earmarked for drug candidate development, cannabinoid sales, and general working capital.

Summary

• InMed Pharmaceuticals Inc. entered into a Securities Purchase Agreement with a single institutional accredited investor for a private placement.
• The private placement involved the sale and issuance of pre-funded warrants to purchase 1,952,363 common shares at a purchase price of $2.561 per share, with a nominal exercise price of $0.0001 per warrant.
• The company also issued short-term preferred investment options to purchase up to 1,952,363 common shares at an exercise price of $2.436 per share, exercisable immediately and expiring eighteen months from the effective date of the Resale Registration Statement.
• The aggregate gross proceeds to the company from this offering were approximately $5 million, before deducting placement agent fees and other offering expenses.
• Concurrently with the private placement, InMed amended 199,115 existing preferred investment options issued to the same investor in October 2023, reducing their exercise price from $16.60 to $2.436 per share, in consideration for the investor's participation and a cash payment of $0.125 per amended option.
• H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a cash fee of 7.5% of the aggregate gross proceeds, a 1.0% management fee, and preferred investment options to purchase 126,904 common shares at an exercise price of $3.2013 per share.

Sentiment

Score: 6

Explanation: The private placement successfully secured needed capital, which is positive for a development-stage pharmaceutical company. However, the significant dilution and associated fees, along with the uncertainty of future option exercises, temper the overall positive sentiment. It's a necessary step for funding but comes with costs to existing shareholders.

Positives

• Successfully raised approximately $5 million in gross proceeds, providing crucial capital for ongoing operations and pipeline development.
• Secured additional potential gross proceeds of approximately $4.75 million if the short-term preferred investment options are fully exercised on a cash basis.
• Amended existing preferred investment options at a significantly reduced exercise price, potentially making them more attractive for future exercise by the investor and simplifying the capital structure for that investor.

Negatives

• The private placement involves the issuance of pre-funded warrants and preferred investment options, which will lead to dilution of existing common shares upon exercise.
• Significant fees and expenses are associated with the offering, including a 7.5% placement agent cash fee, a 1.0% management fee, and the issuance of additional preferred investment options to the placement agent.
• The company explicitly acknowledges that the issuance of securities may result in substantial dilution of outstanding common shares.

Risks

• The securities issued in the private placement have not been registered under the Securities Act or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption.
• The company acknowledges that the issuance of the securities may result in substantial dilution of the outstanding common shares.
• There is no assurance that the short-term preferred investment options will be fully exercised, meaning the potential additional $4.75 million in gross proceeds is not guaranteed.
• The company is subject to potential liquidated damages if it fails to timely file or maintain effectiveness of the resale registration statement or fails to satisfy public information requirements under Rule 144.
• The company is prohibited from effecting certain equity sales, including Variable Rate Transactions, for a period of one year after the Effective Date, which could limit future financing flexibility.
• Known and unknown risk factors could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by forward-looking information.

Future Outlook

The company intends to use the net proceeds from the offering to continue pipeline development of its pharmaceutical drug candidates, support commercial sales of rare cannabinoids through its subsidiary BayMedica LLC, and for general working capital purposes. The company has also committed to filing one or more registration statements with the SEC to cover the resale of the unregistered securities issued in the offering.

Management Comments

• The company intends to use the net proceeds from the offering to continue pipeline development of its pharmaceutical drug candidates, support commercial sales of rare cannabinoids through its subsidiary BayMedica LLC, and for general working capital purposes.

Industry Context

This private placement provides InMed Pharmaceuticals with additional capital, which is crucial for pharmaceutical companies engaged in drug development, a capital-intensive industry. The funding supports ongoing pipeline development and commercialization efforts for rare cannabinoids, aligning with the growing interest in cannabinoid-based therapeutics and the need for sustained investment in biotech R&D.

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of pre-funded warrants and preferred investment options. Existing preferred investment options were amended to a lower exercise price, which could lead to earlier exercise and further dilution.
• Company Operations: The capital raise provides funding for continued pipeline development and commercial sales, which is beneficial for the company's strategic objectives.
• Investors (Purchaser): The institutional investor gained pre-funded warrants and preferred investment options at a favorable price, and had existing options repriced, potentially increasing their upside.
• Placement Agent (H.C. Wainwright & Co., LLC): Received substantial fees and preferred investment options, indicating a positive financial outcome for them.

Next Steps

• File one or more registration statements with the SEC covering the resale of the unregistered securities issued in the offering (Resale Registration Statement).
• Continue pipeline development of pharmaceutical drug candidates.
• Support commercial sales of rare cannabinoids through BayMedica LLC.

Key Dates

Recommendation

Keywords

InMed Pharmaceuticals, Private Placement, SEC Filing, 8-K, Pre-funded Warrants, Preferred Investment Options, Capital Raise, Dilution, Pharmaceuticals, Drug Development, Cannabinoids, BayMedica LLC, H.C. Wainwright & Co., Nasdaq, Accredited Investor, Securities Act, Regulation D, Registration Rights Agreement